The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the world’s largest congress dedicated to multiple sclerosis (MS) research and care, kicks off today in Barcelona. About 9,000 scientists, clinicians, industry leaders, and patient advocates from more than 100 countries are expected…
News
Note: This story was updated Sept. 23, 2025, to correct the generic name of Aubagio from tolebrutinib to teriflunomide. The U.S. Food and Drug Administration (FDA) has delayed by three months its decision on whether or not to approve Sanofi’s tolebrutinib as a treatment for multiple sclerosis (MS),…
People with multiple sclerosis (MS) may receive less frequent treatments with anti-CD20 therapies without increasing their risk of disease activity or disability progression. That’s according to a new meta-analysis of published studies that investigated the use of different dosing schedules for anti-CD20 therapies — approved treatments that deplete the…
Doctors will be able to diagnose multiple sclerosis (MS) faster and with greater accuracy — allowing patients to access treatment and support earlier — following an update to the McDonald criteria, the official guidelines used to diagnose the condition. The revision reflects advances in understanding the biology of…
An international research team has secured nearly $800,000 (about CA$1.1 million) to advance a potential regenerative therapy for multiple sclerosis (MS) toward clinical testing. While existing treatments can slow disease progression, none can repair the nerve damage that has already occurred. This new project aims to change that by…
People with relapsing-remitting multiple sclerosis (RRMS) who started fasting or adopted a ketogenic diet — one low in carbs and rich in fat — for 18 months showed reductions in risk factors for heart and metabolic disease that were similar to those who followed a standard healthy diet, according…
Children and adolescents who go on to develop multiple sclerosis (MS) begin visiting the emergency department more often than their peers as early as a dozen years before their first MS symptoms appear, a new study from Canada suggests. In fact, over an 18-year period, children later diagnosed…
Paramagnetic rim lesions (PRLs), which represent areas of damage in the brain and spinal cord with chronic active inflammation, are highly indicative of multiple sclerosis (MS) in people being evaluated for the disease, a new study reports. The findings support using this imaging biomarker as a useful tool for…
A generic formulation of Zeposia (ozanimod), which won tentative approval for treating multiple sclerosis (MS) from the U.S. Food and Drug Administration (FDA), will be manufactured and supplied by Synthon, based in the Netherlands. Tentative approval means the generic version has met all FDA requirements for…
TG Therapeutics has started enrolling participants in a Phase 3 trial to test a new version of Briumvi (ublituximab-xiiy) that can be injected at home. This change could offer greater convenience and flexibility for people with relapsing forms of multiple sclerosis (MS). The new formulation is given…
Immunic Therapeutics will receive a new U.S. patent covering its experimental therapy, vidofludimus calcium, and some related molecules in people with multiple sclerosis (MS). Titled “Treatment of multiple sclerosis comprising DHODH inhibitors,” the patent explicitly covers the use of the molecules in progressive types of MS, including primary…
The CD20 inhibitor Ocrevus (ocrelizumab) rapidly depletes immune B-cells in people with multiple sclerosis (MS), as expected, but ongoing treatment also leads to changes in immune T-cells, a new study reports. After about six months of treatment, patients experience T-cell changes such as an increase in regulatory…
Octave Bioscience has raised $35.6 million in funding to continue marketing its multiple sclerosis (MS) disease activity test and accelerate the development of a similar tool for Parkinson’s disease. The Multiple Sclerosis Disease Activity (MSDA) test — the first blood test of its kind…
Three biosimilar drugs — approved versions of brand-name therapies that have no clinically meaningful differences compared with their reference products — including one for multiple sclerosis (MS), will soon be available in the Middle East and North Africa (MENA) region under a new partnership between two pharmaceutical companies.
Most children with multiple sclerosis (MS) have chronic active lesions that slowly get bigger over time, and their frequency seems to correlate with the total number of lesions and reduced brain growth, according to a research letter. Changes in disability or cognitive scores over time, however, weren’t significantly associated…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Hope Biosciences‘ adipose-derived mesenchymal stem cells (HB-adMSCs) to treat relapsing-remitting multiple sclerosis (RRMS). RMAT status is given to therapies with compelling proof that they may substantially improve patient outcomes compared with existing…
In the U.S., nearly 4 out of 5 neurologists prescribing therapies for multiple sclerosis (MS) have received payments from pharmaceutical companies that market MS treatments, according to a new analysis. The findings indicate that neurologists who receive payments from a company are significantly more likely to prescribe that…
Health Canada is warning that glatiramer acetate products, used in the country to treat relapsing-remitting multiple sclerosis (MS), may cause a severe allergic reaction called anaphylaxis, which can be life-threatening. The warning follows 11 reported cases of anaphylactic reactions linked to Copaxone — the original brand name of glatiramer…
Targeting a protein called SOX6 could be an effective way to promote myelin repair in people with multiple sclerosis (MS), a study found. Researchers said the results point to a way for new therapies to treat the condition. The study found SOX6 could control the maturation of oligodendrocytes, the…
The United Arab Emirates became the first country to approve tolebrutinib, clearing it to treat adults with nonrelapsing secondary progressive multiple sclerosis (SPMS). Sanofi’s oral BTK inhibitor is also the first approved therapy that directly addresses the chronic inflammation that contributes to disability progression independent of relapses. “The…
A new model using artificial intelligence (AI) suggests that multiple sclerosis (MS) progression is better viewed along a single disease spectrum, rather than as distinct disease types — such as those now used in MS diagnosis and treatment — according to a study led by scientists in Europe. The…
A generic version of Ampyra (dalfampridine), used to improve walking in adults with multiple sclerosis (MS), is now available in the U.S. at a price its developer said is almost $1,000 a month lower than average. Civicascript will charge pharmacies $16 for each 60-tablet bottle, and recommends…
The International Progressive MS Alliance has introduced the MS Clinical and Imaging Data Resource, or CIDR, to accelerate the search for effective treatments for progressive forms of multiple sclerosis (MS) where options are limited. The resource was built in partnership with McGill University in Canada, as well as…
For children and adolescents with multiple sclerosis (MS), receiving treatment with Copaxone (glatiramer acetate) or its generic formulations may reduce relapses by nearly threefold compared with Avonex (interferon beta-1a), according to data from a clinical trial. However, nearly half of patients on Copaxone and one-third of those…
A ketogenic diet — which involves eating a very low amount of carbohydrates and replacing them with fat — may help ease fatigue, improve neurological function, and boost life quality in people with multiple sclerosis (MS), according to a new analysis. Researchers stressed that available data on the effects…
People genetically prone to a higher body mass index (BMI) are also more likely to develop multiple sclerosis (MS), a study finds. The findings confirm an association between being overweight or obese and a higher likelihood of developing MS, and suggest that lifestyle changes to maintain a healthy weight…
While certain autoimmune diseases are linked to an increased risk of digestive system cancers, people with multiple sclerosis (MS) may be less likely to develop some of these malignancies, according to an analysis of published studies. Researchers found that MS patients are at lower risk of developing pancreatic, esophageal,…
High doses of vitamin D provide clinically modest but statistically significant benefits for adults with multiple sclerosis (MS), according to a meta-analysis of published clinical trials. The study found patients who took the supplement saw reductions in disability scores, relapses, and new lesion formation. Those who took vitamin D for…
Researchers have identified a genetic biomarker that predicts whether people with relapsing forms of multiple sclerosis (MS) will respond to glatiramer acetate (sold as Copaxone, among others) therapy. A study based on an analysis of more than 3,000 MS patients showed that those who carry a form of…
Enrollment is complete for a Phase 2 trial testing Zenas Biopharma’s obexelimab in people with relapsing forms of multiple sclerosis (MS). The trial, MoonStone (NCT06564311), is investigating how safe obexelimab is when given as weekly under-the-skin (subcutaneous) injections, and how well it works in approximately 93 participants…